Korean J Urol.  1990 Oct;31(5):648-654.

The Effect of M-VAC (Methotrexate, vinblastine, Doxorubicin and cisplatin) Chemotherapy for Metastatic Transitional Cell Carcinoma of the bladder Preliminary Report

• Lee KS
• Paick JS
• Lee C
• Kim SW

Abstract

We treated 15 patients with metastatic transitional cell carcinoma with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) chemotherapy. Median patient age was 58 years. The site of primary lesion was bladder in all cases. Histologically, these tumors were all identified as transitional cell carcinoma. The average number of cycle were 4.5 and the cycle length varied from 28 days to 94 days (average 38 days). Of these patients, 12 had measurable disease and 6 responded (3 complete and 3 partial remission response rate 50%). Median survival was 10 months in all 16 patients, 17+ months in complete remission and 3.7 months in progression. Complete tumor regression was observed more frequency with local-regional lesions. Toxicity was severe, with 13% of the patient experiencing nadir sepsis, 47% renal toxicity and 20% mucositis. Although overall survival was not prolonged significantly than the historical control group, M-VAC was effective in small proportion of patients (CR : 3/12). The duration of survival of the patients with complete remission was prolonged significantly. Toxicity was severe but tolerable.

Keyword

M-VAC chemotherapy; Bladder tumor

MeSH Terms

Carcinoma, Transitional Cell*
Cisplatin
Doxorubicin*
Drug Therapy*
Humans
Methotrexate
Mucositis
Sepsis
Urinary Bladder Neoplasms
Urinary Bladder*
Vinblastine*
Cisplatin
Doxorubicin
Methotrexate
Vinblastine